Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study
- 460 Downloads
Women with ovarian cancer often undergo chemotherapy involving multiple agents. However, little is known about treatment-related central neurotoxicity in this population. The goal of this cross-sectional study was to assess brain structure and function and neurocognitive abilities in patients with ovarian cancer following first-line chemotherapy. Eighteen patients with ovarian, peritoneal and fallopian tube cancer and eighteen healthy controls matched for gender, age and education participated in the study. The patients were evaluated 1–4 months following completion of first-line taxane/platinum chemotherapy. All participants underwent structural and functional magnetic resonance imaging (MRI), and completed neuropsychological tests of attention, memory and executive functions. Neuroimaging assessments included voxel-based morphometry (VBM) for measuring gray matter (GM) volume, and functional MRI (fMRI) during the N-back working memory task. The results of VBM showed that patients had significantly reduced GM volume compared to healthy controls in the right middle/superior frontal gyrus, and in the left supramarginal gyrus and left inferior parietal lobule. fMRI results indicated significantly decreased activation in patients relative to healthy controls in the left middle frontal gyrus and left inferior parietal lobule during the N-back task (1/2/3-back >0-back). There were no statistically significant differences between the two groups on the neuropsychological tests. This is the first study showing structural and functional alterations involving frontal and parietal regions in patients with ovarian cancer treated with first-line chemotherapy. These findings are congruent with studies involving women with breast cancer, and provide additional supporting evidence for central neurotoxicity associated with taxane/platinum chemotherapy.
KeywordsOvarian cancer Chemotherapy Cognitive MRI fMRI
This study was funded by the Leon Levy Foundation.
Compliance with ethical standards
Conflict of interest
Dr. Correa serves on the Editorial Board of Neuro-Oncology Practice and on the Neurotoxicity Advisory Board for Juno Therapeutics.
Dr. Root reports no conflicts of interest.
Ms. Kryza-Lacombe reports no conflicts of interest.
Ms. Mehta reports no conflicts of interest.
Dr. Karimi reports no conflicts of interest.
Dr. Hensley reports no conflicts of interest.
Dr. Relkin has received remuneration from Eisai, HerbalScience Group, Anavex and Forest for consulting services. He has served as an investigator in clinical trials sponsored by the NIH, DOD, Baxter, Merck, Lilly and Eisai. He is a past recipient of grant support from the Leon Levy Foundation.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- Ahles, T. A., Saykin, A. J., McDonald, B. C., Li, Y., Furstenberg, C. T., Hanscom, B. S., et al. (2010). Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. Journal of Clinical Oncology, 28(29), 4434–4440.CrossRefPubMedPubMedCentralGoogle Scholar
- Benton, L., Hamsher, K., & Sivan, A. (1983). Controlled oral word association test. Multilingual aphasia examination (3rd ed.). San Antonio: Psychological Corporation.Google Scholar
- Cella, D. (1997). Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston: Research and Education Core, Evanston Northwestern Healthcare.Google Scholar
- Conroy, S. K., McDonald, B. C., Smith, D. J., Moser, L. R., West, J. D., Kamendulis, L. M., et al. (2013). Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Research and Treatment, 137(2), 493–502.CrossRefPubMedGoogle Scholar
- Correa, D. D., Satagopan, J., Cheung, K., Arora, A. K., Kryza-Lacombe, M., Xu, Y., et al. (2016). COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors. Neuro-Oncology, 2016. doi: 10.1093/neuonc/now057.
- de Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., Caan, M., Douaud, G., et al. (2012). Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Human Brain Mapping, 33(12), 2971–2983.CrossRefPubMedGoogle Scholar
- Delis, D., Kramer, J., Kaplan, E., & Ober, B. (2000). CVLT-II. New York: The Psychological Corporation.Google Scholar
- Deprez, S., Vandenbulcke, M., Peeters, R., Emsell, L., Smeets, A., Christiaens, M. R., et al. (2014). Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints. Journal of Clinical Oncology, 32(19), 2031–2038.CrossRefPubMedGoogle Scholar
- Heaton, R. K., Walden Miller, S., Taylor, M. J., & Grant, I. (2004). Revised comprehensive norms for an expanded Halstead-Reitan battery: Demographically adjusted neuropsychological norms for african american and caucasian adults. Florida: Psychological Assessment Resources Inc..Google Scholar
- Hensley, M. L., Correa, D. D., Thaler, H., Wilton, A., Venkatraman, E., Sabbatini, P., et al. (2006). Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic Oncology, 102(2), 270–277.CrossRefPubMedGoogle Scholar
- Hess, L. M., Chambers, S. K., Hatch, K., Hallum, A., Janicek, M. F., Buscema, J., et al. (2010). Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. Journal of Supportive Oncology, 8(6), 252–258.CrossRefPubMedGoogle Scholar
- Hess, L. M., Huang, H. Q., Hanlon, A. L., Robinson, W. R., Johnson, R., Chambers, S. K., et al. (2015). Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 139(3), 541–545.CrossRefPubMedPubMedCentralGoogle Scholar
- Kluetsch, R. C., Schmahl, C., Niedtfeld, I., Densmore, M., Calhoun, V. D., Daniels, J., et al. (2012). Alterations in default mode network connectivity during pain processing in borderline personality disorder. Archives of General Psychiatry, 69(10), 993–1002.CrossRefPubMedPubMedCentralGoogle Scholar
- Lopez Zunini, R. A., Scherling, C., Wallis, N., Collins, B., MacKenzie, J., Bielajew, C., et al. (2013). Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging and Behavior, 7(4), 460–477.CrossRefPubMedGoogle Scholar
- McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D., & Saykin, A. J. (2012). Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. Journal of Clinical Oncology, 30(20), 2500–2508.CrossRefPubMedPubMedCentralGoogle Scholar
- McDonald, B. C., Conroy, S. K., Smith, D. J., West, J. D., & Saykin, A. J. (2013). Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain, Behavior, and Immunity, 30(Suppl), S117–S125.CrossRefPubMedGoogle Scholar
- Morrison, J., Swanton, A., Collins, S., & Kehoe, S. (2007). Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews, 4, CD005343.Google Scholar
- Ozols, R. F. (2002). Update on the management of ovarian cancer. Cancer Journal, 8 Suppl 1, S22–30.Google Scholar
- Philip, N. S., Sweet, L. H., Tyrka, A. R., Carpenter, S. L., Albright, S. E., Price, L. H., et al. (2016). Exposure to childhood trauma is associated with altered n-back activation and performance in healthy adults: implications for a commonly used working memory task. Brain Imaging and Behavior, 10(1), 124–135.CrossRefPubMedPubMedCentralGoogle Scholar
- Scherling, C., Collins, B., Mackenzie, J., Bielajew, C., & Smith, A. (2012). Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. Journal of Clinical and Experimental Neuropsychology, 34(5), 543–560.CrossRefPubMedGoogle Scholar
- Scherwath, A., Mehnert, A., Schleimer, B., Schirmer, L., Fehlauer, F., Kreienberg, R., et al. (2006). Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Annals of Oncology, 17(3), 415–423.CrossRefPubMedGoogle Scholar
- Schilder, C. M., Seynaeve, C., Beex, L. V., Boogerd, W., Linn, S. C., Gundy, C. M., et al. (2010). Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology, 28(8), 1294–1300.CrossRefPubMedGoogle Scholar
- Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65(1), 5–29.Google Scholar
- Wechsler, D. (2009). Wechsler memory scale-(WMS-IV). New York: The Psychological Corporation.Google Scholar